CytoMed Therapeutics (GDTC) Competitors $2.25 0.00 (0.00%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$2.15 -0.10 (-4.44%) As of 10/15/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock GDTC vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CALAShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. CytoMed Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences 180 Life Sciences (NASDAQ:ATNFW) and CytoMed Therapeutics (NASDAQ:GDTC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Is ATNFW or GDTC more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A CytoMed Therapeutics N/A N/A N/A Which has higher valuation & earnings, ATNFW or GDTC? 180 Life Sciences has higher earnings, but lower revenue than CytoMed Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACytoMed Therapeutics$50KN/A-$1.84MN/AN/A Do analysts recommend ATNFW or GDTC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor ATNFW or GDTC? In the previous week, CytoMed Therapeutics had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for CytoMed Therapeutics and 0 mentions for 180 Life Sciences. CytoMed Therapeutics' average media sentiment score of 0.42 beat 180 Life Sciences' score of 0.00 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral CytoMed Therapeutics Neutral Do insiders and institutionals believe in ATNFW or GDTC? 0.0% of CytoMed Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryCytoMed Therapeutics beats 180 Life Sciences on 5 of the 5 factors compared between the two stocks. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.37B$6.11B$10.46BDividend YieldN/A2.29%5.73%4.77%P/E RatioN/A22.7785.3627.36Price / SalesN/A465.72601.96132.92Price / CashN/A46.7037.4661.86Price / Book3.6910.5512.426.81Net Income-$1.84M-$52.58M$3.32B$276.80M7 Day Performance1.03%0.09%0.57%0.42%1 Month Performance12.44%15.61%10.52%7.86%1 Year Performance8.17%15.13%72.99%41.24% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics0.1684 of 5 stars$2.25flatN/A+8.2%$0.00$50K0.00N/AGap DownATNFW180 Life SciencesN/A$0.08+33.6%N/A+585.9%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.24+5.1%N/AN/A$0.00$110.87K0.0040Gap DownALVOWAlvotechN/A$1.60+4.6%N/A-49.5%$0.00$560.10M0.004Gap DownARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03+24.8%N/A-33.2%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.10-1.1%N/A+443.5%$0.00$39.19M0.0070BTMDWbioteN/A$0.01+4.2%N/AN/A$0.00$199.07M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.04+13.8%N/A-83.8%$0.00N/A0.008Negative NewsGap DownCALACalithera BiosciencesN/A$0.00-83.3%N/A-80.0%$0.00N/A0.0060Gap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AIMDW Competitors ALVOW Competitors ARAV Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDTC) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
